Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

Abbott Atrial Fibrillation Post Approval Study

NCT05434650 · View on ClinicalTrials.gov ↗

Study Summary

This post-approval study is designed to provide continued real-world clinical evidence to confirm the safety and long-term effectiveness of atrial fibrillation (AF) radiofrequency (RF) technologies (e.g. TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)) for the treatment of AF.

Interventions

  • DEVICE electrophysiology study and ablation with an Abbott Ablation Catheter

Study Locations (20)

California

  • Eisenhower Medical Center — Rancho Mirage
  • Sequoia Hospital — Redwood City

Massachusetts

  • Brigham & Women's Hospital — Boston
  • Beth Israel Deaconess Medical Center — Boston

Tennessee

  • Erlanger Medical Center — Chattanooga
  • Centennial Medical Center — Nashville

Virginia

  • Sentara Norfolk General Hospital — Norfolk
  • Chippenham Hospital — Richmond

Alabama

  • Heart Center Research, LLC. — Huntsville

Arkansas

  • Arkansas Cardiology — Little Rock

Georgia

  • Northside Hospital — Atlanta

Louisiana

  • Ochsner Medical Center — New Orleans

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2022-10-21
Est. Completion 2026-11-30

Sponsor

Abbott Medical Devices

155 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05434650

The ClinicalTrials.gov registry entry for NCT05434650 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 155 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Atrial Arrhythmia appearing as the primary indexed condition, and to 1 intervention — of which electrophysiology study and ablation with an Abbott Ablation Catheter is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05434650 reports 20 study locations spanning 16 distinct geographic areas — top geographies include California, Massachusetts, Tennessee. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05434650 about?

NCT05434650 is a clinical study titled "Abbott Atrial Fibrillation Post Approval Study". This post-approval study is designed to provide continued real-world clinical evidence to confirm the safety and long-term effectiveness of atrial fibrillation (AF) radiofrequency (RF) technologies (e.g. TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)) for the treatment of...

What is the current status of trial NCT05434650?

This trial is currently active not recruiting. The enrollment target is 200 participants. The study started on 2022-10-21. Estimated completion is 2026-11-30.

What conditions does trial NCT05434650 study?

This clinical trial studies the following conditions: Atrial Arrhythmia, Atrial Tachycardia, Atrium; Fibrillation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05434650?

The interventions under investigation include: electrophysiology study and ablation with an Abbott Ablation Catheter (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05434650?

This trial is sponsored by Abbott Medical Devices, which has 155 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05434650 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Georgia, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial